Ian N Bruce

46.7k citations

310 papers · 12.1k indexed · 4 hit papers · h-index 59

Impact in

Rheumatology top 0.02%
- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
Immunology top 0.2%
- Atherosclerosis and Cardiovascular Diseases
- T-cell and B-cell Immunology
- Psoriasis: Treatment and Pathogenesis

Papers in

Rheumatology 238
- Systemic Lupus Erythematosus Research 204
- Rheumatoid Arthritis Research and Therapies 49
Immunology 129
- Atherosclerosis and Cardiovascular Diseases 74
- T-cell and B-cell Immunology 21

Co-authors: Dafna D. Gladman Murray B. Urowitz Richard Furie Sarah Skeoch Eric F. Morand Raj Tummala C.E.M. Griffiths Anne Barton
Journals: Lara D. Veeken (49 papers)Annals of the Rheumatic Diseases (46 papers)Lupus Science & Medicine (15 papers)Lupus (14 papers)Arthritis Research & Therapy (8 papers)
Partner nations: United Kingdom United States Canada

In The Last Decade

Ian N Bruce

296 papers receiving 11.8k citations

Hit Papers

align trajectories log scale

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II) 2023 · 89 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 The Lancet
2019 The Lancet Rheumatology
2019 New England Journal of Medicine
2018 The Lancet

Peers

Countries citing papers authored by Ian N Bruce

Since Specialization

Citations

This map shows the geographic impact of Ian N Bruce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian N Bruce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian N Bruce more than expected).

Fields of papers citing papers by Ian N Bruce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian N Bruce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian N Bruce. The network helps show where Ian N Bruce may publish in the future.

Co-authors

The 25 scholars most cited alongside Ian N Bruce, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ian N Bruce Line = papers co-authored together Ian N Bruce links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Clinical trial eligibility of a real-world connective tissue disease cohort: Results from the LEAP cohort Seminars in Arthritis and Rheumatism ·Sarah Dyball, Anastasia‐Vasiliki Madenidou, Mia Rodziewicz, John A. Reynolds, Ariane L. Herrick, Sahena Haque, Hector Chinoy, Ellen Bruce, Ian N Bruce, Ben Parker	2024	1
2	A vasculitis mimic during pregnancy: autoimmune progesterone dermatitis Rheumatology Advances in Practice ·Anastasia‐Vasiliki Madenidou, Hannah Kither, Ian N Bruce	2024	0
3	Novel Glycomimetics Protect against Glycated Low-Density Lipoprotein-Induced Vascular Calcification In Vitro via Attenuation of the RAGE/ERK/CREB Pathway Cells ·Gary P Sidgwick, Ria Weston, Ayman M. Mahmoud, Andrew Schiro, Ferdinand Serracino‐Inglott, Shikha M. Tandel, Sarah Skeoch, Ian N Bruce, Alan M. Jones, M. Yvonne Alexander, Fiona L. Wilkinson	2024	4
4	AB0610 CHARACTERIZATION OF DISEASE SEVERITY AND ORGAN SYSTEM INVOLVEMENT IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN SRI LANKA- ESTABLISHING A COUNTRY-WIDE LUPUS COHORT Chathurika Dandeniya, D. Munidasa, K. Deshapriya, N. Aravinthan, M. De Silva, G. Kasthuriratna, U. Dissanayake, Asanga H. Udagedara, Priyani Wanigasekara, N. Darshana, Ben Parker, Ian N Bruce, A. Ediriweera	2023	1
5	AB0531 APPLYING THE WORKING DEFINITION OF THE DISEASE MODIFICATION CRITERIA TO LUPUS NEPHRITIS TREATMENTS FROM THE PUBLISHED LITERATURE Annals of the Rheumatic Diseases ·A. Askanase, Richard Furie, Maria Dall’Era, Andrew S. Bomback, Andreas Schwarting, Ming‐Hui Zhao, Ian N Bruce, Munther A. Khamashta, Bernard Rubin, Angela Carroll, Maxine Daniels, Roger A. Levy, Ronald van Vollenhoven, Murray B. Urowitz	2023	1
6	A successful antenatal outcome in a patient with refractory Takayasu’s arteritis treated with tocilizumab throughout pregnancy—a case report Oxford Medical Case Reports ·Behram Khan, Trixy David, Jon Sussman, Louise Simcox, Clare Tower, Calvin Soh, Ian N Bruce	2023	1
7	In-person versus virtual administration of the American College of Rheumatology gold standard cognitive battery in systemic lupus erythematosus: Are they interchangeable? Lupus ·ML Barraclough, JP Diaz-Martinez, Andrea Knight, Kathleen Bingham, Jiandong Su, Mahta Kakvan, (unknown), Maria Carmela Tartaglia, Lesley Ruttan, Joan Wither, May Y. Choi, Dennisse Bonilla, Nicole Anderson, Simone Appenzeller, Ben Parker, Patricia Katz, Dorcas Beaton, R Green, Ian N Bruce, Zahi Touma	2023	2
8	Predictors of British Isles Lupus Assessment Group-based outcomes in patients with systemic lupus erythematosus: Analysis from the Systemic Lupus International Collaborating Clinics Inception Cohort Lupus ·Trixy David, Li Su, Yafeng Cheng, Caroline Gordon, Ben Parker, David Isenberg, John A. Reynolds, Ian N Bruce	2023	0
9	Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: apost hocanalysis of the TULIP-1 and TULIP-2 trials Lara D. Veeken ·Ian N Bruce, Ronald van Vollenhoven, Eric F. Morand, Richard Furie, Susan Manzi, William B. White, Gabriel Abreu, Raj Tummala	2022	20
10	Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance RMD Open ·Gwenda Simons, Ellen M. Janssen, Jorien Veldwijk, Rachael L. DiSantostefano, Matthias Englbrecht, Christine Radawski, L. Valor, Jennifer Humphreys, Ian N Bruce, Brett Hauber, Karim Raza, Marie Falahee	2022	8
11	The BILAG-2004 index is associated with development of new damage in SLE Lara D. Veeken ·Chee‐Seng Yee, Caroline Gordon, Mohammed Akil, Peter Lanyon, Christopher Edwards, David Isenberg, Anisur Rahman, Lee‐Suan Teh, Sofia Tosounidou, Robert S. Stevens, Athiveeraramapandian Prabu, Bridget Griffiths, Neil McHugh, Ian N Bruce, Yasmeen Ahmad, Munther A. Khamashta, Vernon T. Farewell	2022	2
12	The BILAG2004-Pregnancy Index is a valid disease activity outcome measure for pregnant SLE patients Rheumatology Advances in Practice ·Chee‐Seng Yee, Munther A. Khamashta, Mohammed Akil, Rachael Kilding, Ian Giles, David Williams, Ian N Bruce, Caroline Gordon	2022	1
13	Evolving concepts in systemic lupus erythematosus damage assessment Nature Reviews Rheumatology ·Megan R.W. Barber, Sindhu R. Johnson, Dafna D. Gladman, Ann E. Clarke, Ian N Bruce	2021	12
14	Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models Arthritis Research & Therapy ·John A. Reynolds, Jennifer Prattley, Nophar Geifman, Mark Lunt, Caroline Gordon, Ian N Bruce	2021	5
15	The effects of disease activity, inflammation, depression and cognitive fatigue on resting state fMRI in systemic lupus erythematosus Lara D. Veeken ·Michelle Barraclough, Shane McKie, Ben Parker, Rebecca Elliott, Ian N Bruce	2021	10
16	Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR) Lupus Science & Medicine ·Sarah Dyball, Sophie Collinson, Emily Sutton, Eoghan McCarthy, Ian N Bruce, Ben Parker	2021	8
17	CLOK (University of Central Lancashire) ·Kathleen McElhone, Janice Abbott, M. A. Hurley, Jane Burnell, Peter Lanyon, Anisur Rahman, Chee‐Seng Yee, Mohammed Akil, Ian N Bruce, Yasmeen Ahmad, Caroline Gordon, Lee‐Suan Teh	2020	6
18	Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register UCL Discovery (University College London) ·(unknown), (unknown), David Isenberg, Anisur Rahman, David Jayne, Cathy Gordon, Ben Parker, (unknown), (unknown), (unknown), Peter Lanyon, Benjamin Rhodes, B Griffiths, Edward M Vital, C-S Yee, (unknown), Mohamed Akil, N. Erb, (unknown), A. Zoma, N. McHugh, Youssef Harrath, (unknown), MW Beresford, Ian N Bruce	2014	1
19	Derivation and Validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus Carolina Digital Repository (University of North Carolina at Chapel Hill) ·Michelle Petri, A-M Orbai, (unknown), Caroline Gordon, JT Merrill, Paul R. Fortin, Ian N Bruce, David Isenberg, (unknown), Ola Nived, G Sturfelt, Rosalind Ramsey‐Goldman, Sang‐Cheol Bae, JG Hanly, Jorge Sánchez‐Guerrero, A. Clarke, Cynthia Aranow, (unknown), (unknown), (unknown), Kenneth Kalunian, MI Costner, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2011	1
20	Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. PubMed ·Masoud El Magadmi, Yasmeen Ahmad, Wajdi Turkie, Allen P. Yates, Naseem Sheikh, Robert M. Bernstein, Paul N. Durrington, Ian Laing, Ian N Bruce	2006	95

About Ian N Bruce

Ian N Bruce is a scholar working on Rheumatology, Immunology, Hematology, Pathology and Forensic Medicine and Genetics, having authored 310 papers that have together received 12.1k indexed citations. Recurring topics across this work include Systemic Lupus Erythematosus Research (204 papers), Atherosclerosis and Cardiovascular Diseases (74 papers), Rheumatoid Arthritis Research and Therapies (49 papers), Monoclonal and Polyclonal Antibodies Research (44 papers), Autoimmune and Inflammatory Disorders Research (26 papers), Systemic Sclerosis and Related Diseases (26 papers), T-cell and B-cell Immunology (21 papers) and Cytokine Signaling Pathways and Interactions (18 papers). The work is most often cited by research in Rheumatology (8.4k citations), Immunology (6.1k citations), Hematology (1.2k citations), Health Informatics (117 citations) and Radiology, Nuclear Medicine and Imaging (1.9k citations). Ian N Bruce has collaborated with scholars based in United Kingdom, United States and Canada. Frequent co-authors include Dafna D. Gladman, Murray B. Urowitz, Richard Furie, Sarah Skeoch, Eric F. Morand, Raj Tummala, C.E.M. Griffiths, Anne Barton, Yasmeen Ahmad and Caroline Gordon. Their work appears in journals such as Lara D. Veeken, Annals of the Rheumatic Diseases, Lupus Science & Medicine, Lupus and Arthritis Research & Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact